Themis Medicare soars on beginning supply of its pain management product

Themis Medicare is currently trading at Rs. 149.50, up by 5.35 points or 3.71% from its previous closing of Rs. 144.15 on the BSE.

The scrip opened at Rs. 142.80 and has touched a high and low of Rs. 151.00 and Rs. 142.80 respectively. So far 2798 shares were traded on the counter.

The BSE group 'T ' stock of face value Rs. 10 has touched a 52 week high of Rs. 151.00 on 09-Sep-2014 and a 52 week low of Rs. 40.00 on 10-Oct-2013.

Last one week high and low of the scrip stood at Rs. 151.00 and Rs. 124.00 respectively. The current market cap of the company is Rs. 125.03 crore.

The promoters holding in the company stood at 71.65% while Institutions and Non-Institutions held 0.01% and 28.33% respectively.

Themis Medicare has started supply of its research based product, for pain management (API - Aceclofenac based injection) to a Indian Pharma major, under long term agreement. Themis is the first company to develop this injection which is IPR protected.

Themis Medicare is also engaged in supplying its research formulations to well known Pharmaceutical companies in India namely Alkem Lab, Fulford, Intas Pharmaceuticals, IPCA Lab, Cadila Healthcare, Aristo Pharma, Mankind Pharma, Shreya Lifesciences, Nicholas Piramal, Unichem Lab, etc.